Photodynamic Inhibition of Herpes Simplex Virus 1 Infection by Tricationic Amphiphilic Porphyrin with a Long Alkyl

Igor Jurak1, Maja Cokarić Brdovčak1, Lara Djaković1

  • 1Department of Biotechnology, University of Rijeka, Radmile Matejčić 2, HR-51000 Rijeka, Croatia.

Pharmaceutics
|March 29, 2023
PubMed

Insights

A novel photosensitizer, TMPyP3-C17H35, effectively inhibits herpes simplex virus 1 (HSV-1) replication and reduces viral infectivity. This photodynamic therapy approach shows promise for treating viral infections with minimal cytotoxicity.

Area of Science:

  • Photodynamic therapy
  • Antiviral research
  • Virology

Background:

  • Photodynamic therapy (PDT) is a versatile treatment for tumors and microbial infections.
  • Herpes simplex virus 1 (HSV-1) serves as a model for studying PDT effects on enveloped viruses.
  • Current understanding of PDT's molecular mechanisms against viruses is limited.

Purpose of the Study:

  • To investigate the antiviral properties of TMPyP3-C17H35, a novel porphyrin-based photosensitizer.
  • To assess the efficacy and mechanism of TMPyP3-C17H35 in inhibiting HSV-1 replication.
  • To evaluate the potential of TMPyP3-C17H35 as a photodynamic antimicrobial chemotherapy agent.

Main Methods:

  • Treatment of HSV-1 infected cells with light-activated TMPyP3-C17H35.
  • Quantification of viral protein levels (immediate-early, early, and late genes).
  • Assessment of viral yield and infectivity in cell culture supernatant.

Main Results:

  • Light-activated TMPyP3-C17H35 efficiently blocked HSV-1 replication at nanomolar concentrations with low cytotoxicity.
  • Significant reduction in viral protein expression and viral yield was observed.
  • TMPyP3-C17H35 demonstrated efficacy when applied before or shortly after infection, and also reduced free virus infectivity.

Conclusions:

  • Activated TMPyP3-C17H35 is a potent inhibitor of HSV-1 replication.
  • The compound effectively reduces viral infectivity both intracellularly and extracellularly.
  • TMPyP3-C17H35 holds potential as a novel antiviral therapeutic and a model for photodynamic antimicrobial chemotherapy research.

Related Concept Videos

Herpes01:28

Herpes

Herpes simplex type 1 (HSV‑1) is a widespread pathogen responsible for orolabial lesions. It is an enveloped, double-stranded DNA (dsDNA) virus belonging to the family Herpesviridae. Once the virus infects a host cell, its double‑stranded DNA genome is delivered into the nucleus, where a coordinated cascade of immediate‑early, early, and late gene expression directs viral DNA replication, structural protein synthesis, and virion assembly. After primary infection of epithelial cells, HSV-1...
Inhibitors of Viral Protein Synthesis01:30

Inhibitors of Viral Protein Synthesis

Protein synthesis is indispensable for viral replication, as viruses lack the cellular machinery required for this process and must hijack the host's translational apparatus. In response, host cells deploy a critical innate immune defense involving interferons, specialized cytokines that play a central role in inhibiting viral propagation.Upon viral detection, infected cells release interferons that bind to receptors on adjacent uninfected cells, activating the JAK-STAT signaling pathway and...
Antiviral Nucleoside Inhibitors01:22

Antiviral Nucleoside Inhibitors

Antiviral Nucleoside InhibitorsAntiviral nucleoside inhibitors are structural analogs of natural nucleosides that interfere with viral DNA or RNA synthesis. These compounds selectively target viral polymerases due to their resemblance to host nucleosides, thereby disrupting viral genome replication.Mechanism of Acyclovir ActionAcyclovir is a guanosine analog with a three-carbon acyclic side chain. It selectively targets herpes simplex virus type 1 (HSV-1), herpes simplex virus type 2 (HSV-2),...